Description
Product Description:
Erleva, manufactured by Glenmark Pharmaceuticals, is a high-quality medication containing the active ingredient Erlotinib. Each pack of Erleva consists of 30 tablets, with each tablet containing 100 mg of Erlotinib. This medication belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), and it is primarily used in the treatment of certain types of cancer, including non-small cell lung cancer (NSCLC) and pancreatic cancer.
Erlotinib works by targeting and inhibiting the activity of a specific protein called the epidermal growth factor receptor (EGFR), which is often overexpressed or mutated in cancer cells. By blocking the EGFR signaling pathway, Erlotinib helps to slow down or stop the growth and spread of cancer cells, thereby slowing the progression of the disease and improving survival rates in patients with certain types of cancer.
Erleva tablets are intended for oral administration and should be taken as directed by a healthcare professional. They can be taken with or without food, depending on individual preference. The recommended dosage of Erleva may vary depending on the type and stage of cancer being treated, as well as the patient’s overall health and tolerance to treatment.
Clinical studies have shown that Erlotinib, when used alone or in combination with other chemotherapy agents, can significantly improve progression-free survival and overall survival rates in patients with advanced or metastatic NSCLC and pancreatic cancer. Erlotinib may also help to improve symptoms such as cough, shortness of breath, and pain associated with cancer.
Like all medications, Erleva may cause side effects in some patients. Common side effects of Erlotinib may include diarrhea, rash, fatigue, nausea, vomiting, loss of appetite, and skin dryness. More serious side effects such as liver problems, lung problems, and gastrointestinal perforation can occur but are rare. It is important to report any side effects or adverse reactions to a healthcare professional promptly.
Before using Erleva, patients should inform their healthcare provider about any pre-existing medical conditions, medications, or supplements they are taking, as well as any history of allergies or sensitivity to medications. Erlotinib may interact with certain medications, so it is essential to disclose all current medications to avoid potential drug interactions.
In conclusion, Erleva tablets manufactured by Glenmark Pharmaceuticals offer a reliable and effective treatment option for patients with certain types of cancer, including NSCLC and pancreatic cancer. When used as directed under the supervision of a healthcare professional, Erlotinib can help slow the progression of the disease, improve symptoms, and enhance overall quality of life for patients with these malignancies. However, it is essential to weigh the benefits against the risks and to prioritize safety and monitoring to ensure optimal therapeutic outcomes.
Reviews
There are no reviews yet.